data + articles · 7 listed
newest 2016spec sheet10 rows
IPAP is a little-studied member of the PPAP/BPAP family of synthetic 'enhancer' compounds that grew out of Jozsef Knoll's work on selegiline (the pharmacologist who first described this drug class). Where PPAP carries a plain phenyl ring and BPAP a benzofuran, IPAP carries an indole ring, making it the tryptamine-flavored cousin of the series. Enhancers do not force neurotransmitter out of neurons the way stimulants do; they nudge catecholaminergic and serotoninergic neurons to release a little more dopamine, norepinephrine, and serotonin only when those neurons naturally fire. IPAP itself is barely characterized, so almost everything that can be said about it is inferred from its better-studied relatives.
- The tryptamine-flavored member of the PPAP enhancer family
- Impulse-linked, non-forcing dopaminergic/serotonergic angle
- A genuinely early-research frontier
- Understudied, wide-open space
Mechanism
IPAP is understood as a catecholaminergic and serotoninergic activity enhancer, a mechanism defined by the prototypes of its class because IPAP itself has not been directly characterized [1][4]. An enhancer is not a releasing agent. Rather than emptying the nerve terminal the way amphetamine does, it increases the amount of transmitter released per nerve impulse, so it amplifies a neuron's own signaling only while that neuron is genuinely firing [2][3]. In the class prototypes this raises impulse-linked , , and output in regions such as the substantia nigra, locus coeruleus, and raphe [2].
The structure-activity work behind the series showed that the aromatic ring at one end of the 2-propylaminopentane backbone tunes potency and selectivity; swapping the phenyl of PPAP for a benzofuran is what produced the far more potent BPAP [1]. IPAP carries an indole ring instead, which is notable because the indole (tryptamine) motif ties the molecule to the body's own enhancer signaling: the endogenous enhancers beta-phenylethylamine and tryptamine are ligands at the trace amine-associated receptor (TAAR1), the target now thought to underlie the enhancer effect [5]. Like its relatives, IPAP is expected to be carried into neurons by the monoamine transporters, where the benzofuran prototype also adds mild reuptake inhibition [6].
Two features carry across the whole class and are worth keeping in mind for IPAP. First, the dose-response is bell-shaped and unusually narrow, with the effect appearing in a very low concentration window and fading again at higher doses, so more is emphatically not better [2]. Second, the negative is the active form. Whether IPAP matches the potency, selectivity, or neuroprotective profile of PPAP and BPAP has not been established in published work [1][7].
receptor fingerprint
Impulse-linked catecholamine / releaseenhances (not releases)
TAAR1 (trace amine receptor)agonist (proposed)
Monoamine transporters ( / SERT / NET)substrate; mild reuptake block
Safetyrisks and cautions, not medical advice
IPAP has essentially no human safety data; it is a research-use-only compound. In theory the enhancer mechanism is gentler than a releasing stimulant because it works with your own impulse firing rather than forcing release, but that is animal-model reasoning about the class, not proven safety for IPAP in people. Because it raises monoamine signaling, be cautious about combining it with MAOIs, SSRIs, or other serotonergic or dopaminergic drugs. The narrow, bell-shaped dose-response also makes overshooting easy. Skip it in pregnancy or breastfeeding for lack of data.
Subjective profileweighing the evidence above
The honest answer is that nobody knows. Its pharmacology is inferred from PPAP and BPAP rather than measured, there is no human safety data, and the enhancer class has a narrow bell-shaped dose response that makes overshooting easy. An interesting frontier and a poor purchase.
Resources
This entry is here for reference.
Research
- 1996first cited(-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants…
- 2016most recentThe significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015)
- 1.Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain
- 2.(-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain
- 3.(-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons
- 4.Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives
- 5.Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives
- 6.Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane
- 7.The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015)
7 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
How is IPAP different from PPAP and BPAP?
Same enhancer backbone, different ring. PPAP has a plain phenyl ring, BPAP a benzofuran, and IPAP an indole; the indole is what makes it the tryptamine-like member of the family. In the prototypes the ring choice changes potency a lot, but IPAP's own numbers aren't published.
Is there human data on IPAP?
No. There's essentially no published research on IPAP specifically, so treat it as a research curiosity rather than an established nootropic; almost everything known is inferred from its relatives.
What does an 'enhancer' actually do?
Instead of dumping transmitter into the synapse like a stimulant does, an enhancer makes a neuron release a little more per impulse, and only when it's already firing. That's why the class is described as amplifying your own signaling rather than overriding it.
Why does dose matter so much?
The enhancer effect is bell-shaped and narrow in the prototypes: it appears at very low amounts and vanishes at higher ones. So with this class, more is not better, and IPAP's exact window isn't known.
Limitations of the evidence
- No human safety data
- Long-term effects unknown
Notes and cautions
- Bell-shaped, narrow dose-response, so overshooting is easy
- Research-chemical purity varies by source